ASCO 2025 Highlights

Chicago, May 30–June 3, 2025

Get the OncoAlert Newsletter

Your role

Your country

How we use your details

Every week, and every day during the major congresses. Free.

News

The faculty’s updates from ASCO 2025, newest first.

Prostate cancer at ASCO 2025
Genitourinary. Dr. Natalia Gandur. Expert pick. In Spanish.
CBM588 with nivolumab and ipilimumab in kidney cancer
Genitourinary. Dr. Miguel Zugman. Interview.
CheckMate 214: the nine-year final results
Genitourinary. Dr. Brian Rini. Interview.
Metastatic castration-resistant prostate cancer at ASCO 2025
Genitourinary. Dr. Natalia Gandur. Expert pick. In Spanish.
KIM-1 in renal cell carcinoma
Genitourinary. Dr. Marc Machaalani. Interview.
Bladder cancer: antibody-drug conjugates, today and tomorrow
Genitourinary. Dr. Brian Rini. Interview.

The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.

Email address

Your role

Your country

How we use your details

ASCO 2025 Highlights

News

Prostate cancer at ASCO 2025

CBM588 with nivolumab and ipilimumab in kidney cancer

CheckMate 214: the nine-year final results

Metastatic castration-resistant prostate cancer at ASCO 2025

KIM-1 in renal cell carcinoma

Bladder cancer: antibody-drug conjugates, today and tomorrow

The week in oncology, in your inbox